BMS Eyes Role for New CAR-T in Post-BCMA Multiple Myeloma

BMS eyes role for new CAR-T in post-BCMA multiple myeloma

BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.

BMS Achieves Milestone with Next-Generation CAR-T Therapy for Multiply-Treated Myeloma Patients

GPRC5D-Targeting Approach Positions Company to Expand Post-BCMA Treatment Options As reported on Fierce BioTech, Bristol Myers Squibb announced positive results from its pivotal Quintessential trial evaluating arlocabtagene autoleucel, a genetically modified T-cell therapy directed against the GPRC5D protein. The trial successfully achieved its primary objective, validating the approach as physicians seek alternatives for patients whose […]